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Two papers describing mice deficient in signaling
lymphocyte activation molecule and 2B4 represent the
first accounts of immune phenotypes in animals lack-
ing members of the SLAM family of receptors. The
findings provide definitive evidence of the importance
of SLAM-related receptors in the regulation of T cell,
macrophage, and natural killer cell functions.
 
The SLAM Family of Immune Cell Receptors.
 
The signal-
ing lymphocyte activation molecule (SLAM) family is a
group of six immunoglobulin-like receptors named SLAM
(or CD150), 2B4 (or CD244), Ly-9 (or CD229), NK-T-B
antigen (NTB-A) (or Ly-108), CD84 and CD2-like receptor
activating cytotoxic T cells (CRACC) (1, 2). These receptors
are differentially expressed in various immune cell types
and are close relatives of the CD2 family. Some, including
SLAM, NTB-A, and CRACC, are self-ligands. At least
one, 2B4, is implicated in heterotypic interactions with
another immune cell receptor, CD48. SLAM is also the
immune cell-specific receptor for measles virus in humans.
Until now, little was known regarding the physiological
functions mediated by the SLAM family. Data from exper-
iments in which cells were treated with antibodies or
ligands presumed to stimulate SLAM-related receptors,
although at times contradictory, suggested that SLAM-
related receptors modulate the immune response.
The notion that SLAM family receptors are immunoreg-
ulatory was supported by the observation that they associate,
by way of cytoplasmic tyrosine-based motifs, with the small
SH2 domain–containing adaptor SAP (2, 3). SAP is ex-
pressed in T cells and NK cells and is mutated in X-linked
lymphoproliferative (XLP) disease, a human immune disorder
characterized by a dysregulated immune response to Epstein-
Barr virus (EBV) infection. Since SAP allows SLAM-related
receptors to associate with the Src-related protein tyrosine
kinase Fyn and to mediate protein tyrosine phosphorylation
signals (4–6), it was postulated that XLP may be the result
of inadequate SLAM family receptor functions in cells nor-
mally expressing SAP. In agreement with this, defects in
CD4
 
 
 
 and CD8
 
 
 
 T cell functions were described in SAP-
deficient mice (7–9). The impact of SAP deficiency on NK
cell functions in mice remains to be examined.
In spite of the mounting evidence that SLAM-related
receptors utilize SAP in their signaling mechanism, some
data suggest that they can mediate functions in the absence
of SAP (1, 2). First, SLAM-related receptors are abundantly
expressed in cell types that do not express SAP, including
macrophages and DCs. These cell types and NK cells con-
tain a SAP homologue termed EAT-2, which can associate
with SLAM-related receptors (1, 2). Whereas the role of
EAT-2 in cell signaling is not known, EAT-2 lacks the
motif that enables SAP to activate Fyn. On that basis, EAT-2
may have a function distinct from that of SAP. Second,
antibody-mediated engagement of 2B4 on NK cells derived
from XLP patients was reported by one group to inhibit,
rather than activate, NK cell–mediated killing (10). Thus,
2B4 may mediate an alternate signal, leading to NK cell
inhibition, in the absence of SAP. Whether this signal is due
to EAT-2 is not known. Third, SLAM-related receptors
were reported to associate with other molecules (such as the
protein tyrosine phosphatase SHP-2) and to mediate certain
types of biochemical signals (such as Akt activation) in the
absence of SAP. Nevertheless, these data were primarily
generated through overexpression studies in nonimmune
cells, and their physiological significance is unclear.
 
Defects in CD4
 
 
 
 T Cell and Macrophage Functions in
SLAM-deficient Mice.
 
SLAM is a homotypic receptor
found on T cells, B cells, macrophages, and DCs (1, 2). Its
expression is typically low in resting cells and is augmented
upon cell activation. A possible role for SLAM was first
characterized in human T cells (11). Engagement of SLAM
by anti-SLAM mAbs evoked TCR-independent CD4
 
 
 
 T
cell proliferation and IFN-
 
 
 
 secretion, but not IL-4 pro-
duction, by previously activated human T cells. This led to
the idea that SLAM was a novel activating receptor on
T cells that favored T
 
H
 
1 cytokine production. Subse-
quent studies with mouse T cells failed to confirm that an-
tibody-mediated SLAM ligation was sufficient to trigger T
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cell activation (12). Nonetheless, SLAM-specific antibodies
moderately enhanced mouse T cell proliferation and IFN-
 
 
 
secretion in response to low doses of anti-CD3 mAb. This
effect was also observed in T cells derived from SAP-defi-
cient mice, indicating that these responses were SAP inde-
pendent (Fig. 1 A; reference 13). However, a significant
limitation of these studies was that it was not known
whether the anti-SLAM antibodies were triggering or
blocking the function of SLAM.
In this issue, Wang et al. report the phenotype of mice
lacking SLAM (14). They found that 
 
Slam
 
 
 
/
 
 
 
 CD4
 
 
 
 T
cells had a severe defect in TCR-mediated production of
IL-4 in vitro. Surprisingly, secretion of IFN-
 
 
 
 was only
slightly enhanced. Although the impact of SLAM defi-
ciency on IL-4 provides evidence for the importance of
SLAM in immunity, the lack of a substantial effect on IFN-
 
 
 
is intriguing. Most likely, there is redundancy with other
receptors having IFN-
 
 
 
–inducing functions that compen-
sate for the absence of SLAM. In support of this, it is
known that T cells express other SLAM family receptors,
including Ly-9 and NTB-A. The small increase in IFN-
 
 
 
production observed in SLAM-deficient T cells also sug-
gests that SLAM signaling may inhibit rather than augment
IFN-
 
 
 
 release. Therefore, the anti-SLAM antibodies used
in previous studies were possibly antagonists.
Considering the marked defect in IL-4 production in
SLAM-deficient CD4
 
 
 
 T cells, the lack of an effect of anti-
SLAM antibodies on IL-4 release is perplexing. One inter-
pretation is that anti-SLAM antibodies impinge on only
part of the function of SLAM, either by affecting selective
SLAM–SLAM interactions or by altering the surface distri-
bution of SLAM. Consequently, anti-SLAM antibodies
may influence the coupling of SLAM to pathways regulat-
ing IFN-
 
  
 
without interfering with those controlling IL-4.
A clearer understanding of these contradictory observations
will likely be provided by a better biophysical and bio-
chemical analysis of SLAM and SLAM-associated signaling
pathways in T cells.
Similar to SLAM-deficient T cells, T cells from 
 
Sap
 
 
 
/
 
 
 
mice have markedly reduced IL-4 production (7, 8).
This similarity implies that SLAM regulates IL-4 release
through its interaction with SAP (Fig. 1 A). Moreover, it
suggests that the defect in IL-4 production in 
 
Sap
 
 
 
/
 
 
 
 T
cells is largely due to a block in SLAM receptor signal
transduction. However, the IL-4 defect was more drastic
in T cells from 
 
Sap
 
 
 
/
 
 
 
 animals than 
 
Slam
 
 
 
/
 
 
 
 animals, rais-
ing the possibility that other SLAM family receptors regu-
late IL-4 through a SAP-dependent pathway. In spite of
the clear link between SLAM and IL-4, it must be empha-
sized that the defects in CD4
 
 
 
 T cell help seen in vivo in
SAP-deficient mice do not seem to be due to a simple
lack of IL-4 production (9). Other as yet unidentified
T
 
H
 
2-related alterations appear to be implicated. Hence, to
establish the relative importance of SLAM dysfunctions in
SAP-dependent immune defects it will be crucial to assess
the extent of functional T cell abnormalities in vivo in
 
Slam
 
 
 
/
 
 
 
 mice.
SLAM-deficient macrophages were found to exhibit ab-
normal functions in vitro and in vivo (14). Production of
IL-12, TNF-
 
 
 
,
 
 
 
and nitric oxide (NO) in response to LPS,
with or without IFN-
 
 
 
, was diminished in 
 
Slam
 
 
 
/
 
 
 
 perito-
neal macrophages. Furthermore, IL-6 secretion in response
to LPS alone was enhanced. In contrast, IL-12 and TNF-
 
 
 
secretion triggered by Toll-like receptor agonists, such as
CpG DNA and peptidoglycan, and the capacity of macro-
phages to present antigen to T cells were normal. In vivo
studies showed that the ability of C57BL/6 mice to clear
 
Leishmania major
 
 infection was compromised in the absence
of SLAM. In this mouse strain, healing of 
 
Leishmania major
 
lesions is known to rely heavily on macrophage functions,
including IL-12, TNF-
 
 
 
, and NO production.
The mechanism by which SLAM regulates macrophage
responses to LPS was not established. Since stimulation with
anti-SLAM antibodies was sufficient to trigger IL-12 secre-
tion and inhibit IL-6 release by inflammatory macrophages,
it is plausible that SLAM–SLAM interactions between
neighboring macrophages induce a signal that influences cy-
tokine release in response to LPS. However, given the simi-
larities between LPS, CpG, and peptidoglycan signaling, it is
not clear why the lack of SLAM expression would only af-
fect LPS-triggered responses. Moreover, the nature of the
SLAM signals regulating IL-12 and IL-6 synthesis in macro-
phages remains to be determined. Macrophages do not ex-
press SAP but do express EAT-2 (2, 3). As discussed above,
EAT-2 may or may not play a role analogous to that of SAP
in SLAM family receptor signaling. It is also conceivable
that SLAM regulates macrophage function independently of
SAP-related adaptors. The characterization of SLAM-induced
biochemical signals in macrophages and of the role of EAT-2
in these cells will help clarify these issues.
 
2B4-deficient Mice Reveal an Inhibitory Role for 2B4 in NK
Cells.
 
2B4 is found on NK cells, CD8
 
 
 
 T cells, 
 
  
 
 T
cells, and monocytes (1, 2). Its ligand is CD48, a glyco-
phosphatidylinositol (GPI)-linked receptor broadly expressed
on immune cells. Previous studies showed that engagement
of 2B4 on human or mouse NK cells by anti-2B4 anti-
bodies results in production of IFN-
 
 
 
 (1, 2). Further-
more, anti-2B4 antibodies trigger NK cell–mediated killing
in reverse antibody-dependent cellular cytotoxicity assays.
These effects were observed to be seriously compromised
in XLP-derived NK cells, implying that they rely on the
ability of 2B4 to associate with SAP in humans. Engage-
ment of 2B4 expressed on CD8
 
 
 
 T cells by CD48 was also
reported to enhance TCR-mediated cytotoxicity (15).
Thus, together these results led to the belief that 2B4 is an
activating receptor, which augments the responsiveness of
NK cells and CD8
 
 
 
 T cells.
In this issue, Lee et al. report the phenotype caused by
lack of 2B4 expression in mice (16). Unexpectedly, they
observed that cell-mediated cytotoxicity and IFN-
 
 
 
 secre-
tion was enhanced rather than diminished in 
 
2b4
 
 
 
/
 
 
 
 NK
cells. The ability of NK cells to eliminate tumor cells in an
intraperitoneal tumor clearance assay was also increased.
These altered functions were fully dependent on expression 
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of CD48 on target cells and were blocked by addition of
anti-CD48 antibodies. They were also restored in 2B4-
deficient NK cells by retrovirus-mediated expression of the
long form of 2B4, but not the short form, which has fewer
tyrosine-based motifs in its cytoplasmic domain. These un-
anticipated results imply that 2B4 is primarily an inhibitory
receptor in mouse NK cells and suggest that the ability of
anti-2B4 antibodies to trigger NK cell functions in mice,
and possibly humans, may reflect their capacity to block
2B4–CD48 interactions.
However, there are still compelling data indicating that
expression of CD48 on target cells can enhance the capac-
ity of human NK cells to kill (17). Additionally, one group
reported that target cell killing was defective in NK cells
from an XLP patient even in the absence of additional anti-
2B4 antibodies (18). There is also convincing evidence that
the presence of CD48 on 2B4
 
 
 
 CD8
 
 
 
 mouse T cells en-
hances antigen-induced T cell cytotoxicity (15). Therefore,
2B4 may be able to act either as an inhibitory receptor or as
an activating receptor (Fig. 1 B).
One scenario is that 2B4 mediates these opposite effects
in different subsets of NK cells. In support of this, Moretta
et al. reported that anti-2B4 antibody stimulation inhibited
NK cell activity in immature human NK cells, whereas it
enhanced the function of mature cells (19). These differen-
tial effects were postulated to result from expression of SAP
in mature but not in immature NK cells. This notion is also
consistent with the finding made by the same group that
2B4 ligation was inhibitory rather than activating in NK
cells from XLP patients (10). It may also explain the finding
of Lee et al. that 
 
Sap
 
 RNA was present in mouse lympho-
kine-activated killer cells but not in BM-derived mouse NK
cells (16). However, since the impact of 2B4 deficiency
was similar in these two NK cell populations doubts remain
regarding the consequences of differential SAP expression
in mouse NK cells.
Other variables could explain a differential capacity of
2B4 to mediate positive or negative signaling (Fig. 1 B),
and these variables may be different in human and mouse
NK cells. The dominant inhibitory effect of 2B4 in mouse
NK cells may relate to their preferential expression of
EAT-2 over SAP. Indeed, unlike 
 
Sap
 
 mRNA, 
 
Eat-2
 
mRNA was detectable both in mouse lymphokine-acti-
vated killer cells and in BM-derived mouse NK cells (16).
In contrast, as suggested by some of the analyses of XLP-
derived NK cells, the apparent activating effect of 2B4 in
human NK cells may relate to preferential expression of
SAP. It is also possible that 2B4-mediated inhibition relates
to the capacity of 2B4 to mediate signals in the absence of
SAP and EAT-2. In support of this, transient transfection
experiments showed that 2B4 was able to associate with
SHP-2 in cells lacking SAP and EAT-2 (20). However, this
finding was not confirmed by others (10, 21). A careful
analysis of SAP and EAT-2 expression in human and
mouse NK cells, in addition to a characterization of 2B4-
mediated functions and signals in mice lacking SAP and/or
EAT-2, will test these ideas.
 
Lessons from Mice Lacking SLAM-related Receptors.
 
The
reports of Wang et al. (14) and Lee et al. (16) yield several
important conclusions. First, they provide firm evidence of
the involvement of SLAM-related receptors in immune
regulation. Second, they indicate that the previously pub-
lished studies using mAb stimulation led to some miscon-
ceptions regarding the roles of SLAM family receptors in
vivo. This may relate to the fact that the antibodies were
blocking rather than stimulating the functions of SLAM-
related receptors. It is also plausible that the antibodies
were affecting only a subset of the functions of SLAM-
related receptors, thus exposing a biased view of their roles.
And third, these manuscripts coupled with other published
findings suggest that a given SLAM-related receptor may
have the ability to mediate different, potentially even op-
Figure 1. Functions of SLAM family re-
ceptors are regulated by differential expression
of SAP-related adaptors. (A) Model of SLAM
function. In T cells expressing SAP, SLAM–
SLAM interactions trigger selective up-regula-
tion of IL-4 secretion in response to antigen
receptor stimulation. Although the down-
stream targets responsible for this activity are
not yet understood, they may involve previ-
ously described SLAM-SAP effectors, such
as Fyn, SHIP-1, Dok-1, Dok-2, Shc, and
Ras-GAP (5). In the absence of SAP, SLAM
could mediate a different signal, which may
lead to down-regulation of IFN-  secretion.
(B) Model of 2B4 function. In NK cells
containing SAP, 2B4–CD48 interactions
enhance cytotoxicity and secretion of IFN- .
This response may involve known targets of
2B4-SAP signaling, such as Vav-1, c-Cbl,
and SHIP-1 (22, 23). In the presence of
EAT-2, 2B4 could induce NK cell inhibition.
In the absence of both SAP and EAT-2,
2B4 could trigger yet another signal that
inhibits NK cell functions. 
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posite, signals and functions in different cell populations or
activation states. This ability may relate to differential ex-
pression of SAP-related adaptors (Fig. 1) or to other as yet
unappreciated factors. Such flexibility would give SLAM-
related receptors an exquisite degree of control during an
immune response.
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